These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 16842888)
1. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Imoukhuede EB; Berthoud T; Milligan P; Bojang K; Ismaili J; Keating S; Nwakanma D; Keita S; Njie F; Sowe M; Todryk S; Laidlaw SM; Skinner MA; Lang T; Gilbert S; Greenwood BM; Hill AV Vaccine; 2006 Oct; 24(42-43):6526-33. PubMed ID: 16842888 [TBL] [Abstract][Full Text] [Related]
2. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. Moorthy VS; Pinder M; Reece WH; Watkins K; Atabani S; Hannan C; Bojang K; McAdam KP; Schneider J; Gilbert S; Hill AV J Infect Dis; 2003 Oct; 188(8):1239-44. PubMed ID: 14551895 [TBL] [Abstract][Full Text] [Related]
5. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197 [TBL] [Abstract][Full Text] [Related]
6. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727 [TBL] [Abstract][Full Text] [Related]
7. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Bejon P; Mwacharo J; Kai OK; Todryk S; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV Vaccine; 2006 May; 24(22):4709-15. PubMed ID: 16621181 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620 [TBL] [Abstract][Full Text] [Related]
10. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. McConkey SJ; Reece WH; Moorthy VS; Webster D; Dunachie S; Butcher G; Vuola JM; Blanchard TJ; Gothard P; Watkins K; Hannan CM; Everaere S; Brown K; Kester KE; Cummings J; Williams J; Heppner DG; Pathan A; Flanagan K; Arulanantham N; Roberts MT; Roy M; Smith GL; Schneider J; Peto T; Sinden RE; Gilbert SC; Hill AV Nat Med; 2003 Jun; 9(6):729-35. PubMed ID: 12766765 [TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466 [TBL] [Abstract][Full Text] [Related]
18. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B; PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537 [TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling. Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]